135 related articles for article (PubMed ID: 3321648)
21. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
22. [Immunosuppressive drugs in the prevention and treatment of GVHD after allogenic bone marrow transplantation].
Basić-Jukić N; Labar B
Acta Med Croatica; 2003; 57(2):131-9. PubMed ID: 12879693
[TBL] [Abstract][Full Text] [Related]
23. Prevention and treatment of acute graft-versus-host disease.
Neudorf S; Filipovich A; Ramsay N; Kersey J
Semin Hematol; 1984 Apr; 21(2):91-100. PubMed ID: 6377502
[No Abstract] [Full Text] [Related]
24. Marrow transplantation: the Seattle experience.
Storb R
Tokai J Exp Clin Med; 1985 Jun; 10(2-3):75-83. PubMed ID: 3914747
[TBL] [Abstract][Full Text] [Related]
25. Approaches to graft-versus-host disease following bone marrow transplantation in monkeys and man.
Dicke KA; Spitzer G; Peters L; Stevens EE; Hendriks W; McCredie tkb
Transplant Proc; 1978 Mar; 10(1):217-21. PubMed ID: 416529
[No Abstract] [Full Text] [Related]
26. A randomized prospective trial comparing cyclosporine and methotrexate given for prophylaxis of graft-versus-host disease after bone marrow transplantation.
Biggs JC; Atkinson K; Gillett E; Downs K; Concannon A; Dodds A
Transplant Proc; 1986 Apr; 18(2):253-5. PubMed ID: 3515659
[No Abstract] [Full Text] [Related]
27. Bone marrow transplantation for correction of severe aplastic anemia and primary immunodeficiency.
Dupont B; Flomenberg N; O'Reilly RJ
Ann Clin Res; 1981; 13(4-5):358-66. PubMed ID: 7039487
[No Abstract] [Full Text] [Related]
28. A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: methotrexate/prednisone v cyclosporine A/prednisone.
Forman SJ; Blume KG; Krance RA; Miner PJ; Metter GE; Hill LR; O'Donnell MR; Nademanee AP; Snyder DS
Transplant Proc; 1987 Feb; 19(1 Pt 3):2605-7. PubMed ID: 3079090
[No Abstract] [Full Text] [Related]
29. Transplantation of T lymphocyte depleted bone marrow to prevent graft-versus-host disease: its implications for fetal liver transplantation.
Champlin RE; Mitsuyasu RT; Gale RP
Prog Clin Biol Res; 1985; 193():315-25. PubMed ID: 3911215
[No Abstract] [Full Text] [Related]
30. Results of four different protocols for prophylaxis against graft-versus-host disease.
Tollemar J; Ringdén O; Bäckman L; Janossy G; Lönnqvist B; Markling L; Philstedt P; Sundberg B
Transplant Proc; 1989 Feb; 21(1 Pt 3):3008-10. PubMed ID: 2650414
[No Abstract] [Full Text] [Related]
31. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
[TBL] [Abstract][Full Text] [Related]
32. Graft vs graft reaction resulting in the elimination of maternal cells in a SCID patient with maternofetal GVHd after an HLA identical bone marrow transplantation.
Le Deist F; Raffoux C; Griscelli C; Fischer A
J Immunol; 1987 Jan; 138(2):423-7. PubMed ID: 3540121
[TBL] [Abstract][Full Text] [Related]
33. Marrow transplantation from unrelated HLA-matched volunteer donors.
Beatty PG; Hansen JA; Anasetti C; Sanders J; Buckner CD; Storb R; Thomas ED
Transplant Proc; 1989 Feb; 21(1 Pt 3):2993-4. PubMed ID: 2650410
[No Abstract] [Full Text] [Related]
34. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
35. Cyclosporin a: a new era in organ transplantation.
DeBakey ME
Compr Ther; 1984 Feb; 10(2):7-15. PubMed ID: 6368108
[No Abstract] [Full Text] [Related]
36. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
[TBL] [Abstract][Full Text] [Related]
37. Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: addition of cytosine arabinoside to the pretransplant conditioning prevents rejection.
Bozdech MJ; Sondel PM; Trigg ME; Longo W; Kohler PC; Flynn B; Billing R; Anderson SA; Hank JA; Hong R
Exp Hematol; 1985 Dec; 13(11):1201-10. PubMed ID: 3905427
[TBL] [Abstract][Full Text] [Related]
38. Prevention of graft-versus-host disease on an individual basis.
Aschan J; Ringdén O; Andström E; Ljungman P; Remberger M
Transplant Proc; 1994 Jun; 26(3):1823-4. PubMed ID: 8030155
[No Abstract] [Full Text] [Related]
39. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
[TBL] [Abstract][Full Text] [Related]
40. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
van Burik JA; Carter SL; Freifeld AG; High KP; Godder KT; Papanicolaou GA; Mendizabal AM; Wagner JE; Yanovich S; Kernan NA
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1487-98. PubMed ID: 18022579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
